klacid paediatric suspension 125 mg5 ml
abbott medical laboratories ltd, israel - clarithromycin - granules for reconstitution - clarithromycin 125 mg / 5 ml - clarithromycin - clarithromycin - bronchitis, pharyngitis, tonsilitis pneumonia skin infections due to susceptible microorganisms. treatment of mycobacterium avium complex in patients with aids. treatment of otitis media.
klacid 250 milligram tablets
b & s healthcare - clarithromycin - tablets - 250 milligram
klacid la 500 milligram modified-release tablets
abbott laboratories ireland ltd - clarithromycin - modified-release tablets - 500 milligram
klacid forte 500 mg film-coated tablets
mylan ire healthcare limited - clarithromycin - film-coated tablet - 500 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for treatment of infections due to susceptible organisms. such infections include. 1. lower respiratory tract infections (e.g. bronchitis, pneumonia). 2. upper respiratory tract infections (e.g. pharyngitis, sinusitis). 3. skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas). 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localised infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii. 5. is indicated also for the prevention of disseminated mycobacterium avium complex infection in hiv- infected patients with cd4 lymphocyte counts less than or equal to 100/mm3. 6. in the presence of acid suppression is indicated for the eradication of h. pylori, resulting in decreased recurrence of duodenal ulcer.
klacid iv 500mg powder for concentrate for solution for infusion
mylan ire healthcare limited - clarithromycin - powder for concentrate for solution for infusion - 500 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for treatment of infections caused by susceptible organisms in the following conditions: lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia. upper respiratory tract infections for example, sinusitis and pharyngitis. skin and soft tissue infections.
klacid 250 mg film-coated tablets
mylan ire healthcare limited - clarithromycin - film-coated tablet - 250 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for the treatment of infections due to susceptible organisms. such infections include: 1. lower respiratory tract infections (e.g. bronchitis, pneumonia). 2. upper respiratory tract infections (e.g. pharyngitis, sinusitis). 3. skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas). 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localised infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii. 5. clarithromycin is indicated for the prevention of disseminated mycobacterium avium complex infection in hivinfected patients with cd4 lymphocyte counts less than or equal to 100/mm3. 6. clarithromycin in the presence of acid suppression is indicated for the eradication of h. pylori, resulting in decreased recurrence of duodenal ulcer. (see further information).
klacid 250mg/5ml granules for oral suspension
mylan ire healthcare limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - clarithromycin - granules for oral suspension - clarithromycin 250 mg/5ml - antibacterials for systemic use
klacid 250mg/5ml granules for oral suspension
viatris healthcare limited - clarithromycin - granules for oral suspension - macrolides; clarithromycin
klacid
viatris limited - clarithromycin 250mg; ; clarithromycin 250mg - film coated tablet - 250 mg - active: clarithromycin 250mg excipient: croscarmellose sodium hydrated silica hyprolose hypromellose magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc quinoline yellow sorbic acid sorbitan oleate starch stearic acid titanium dioxide vanillin active: clarithromycin 250mg excipient: colloidal silicon dioxide croscarmellose sodium ethanol hyprolose hypromellose magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc purified water quinoline yellow sorbic acid sorbitan oleate starch stearic acid titanium dioxide vanillin - klacid tablets are indicated for treatment of infections caused by susceptible organisms. such infections include: · respiratory tract infections including bronchitis, pneumonia, tonsillitis, sinusitis and pharyngitis. · skin and soft tissue infections such as folliculitis, cellulitis and erysipelas. · disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localized infections due to mycobacterium chelonae, mycobacterium fortuitum, or mycobacterium kansasii. · prevention of disseminated mycobacterium avium complex infection in hiv-infected patients with cd4 lymphocyte counts less than or equal to 100/mm3. · clarithromycin in the presence of acid suppression is indicated for the treatment of duodenal ulcer and in reducing the rate of ulcer recurrence.
klacid
viatris limited - clarithromycin 500mg; ; clarithromycin 500mg - film coated tablet - 500 mg - active: clarithromycin 500mg excipient: croscarmellose sodium hydrated silica hyprolose hypromellose magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc quinoline yellow sorbic acid sorbitan oleate stearic acid titanium dioxide vanillin active: clarithromycin 500mg excipient: colloidal silicon dioxide croscarmellose sodium ethanol hyprolose hypromellose magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc purified water quinoline yellow sorbic acid sorbitan oleate stearic acid titanium dioxide vanillin - klacid tablets are indicated for treatment of infections caused by susceptible organisms. such infections include: · respiratory tract infections including bronchitis, pneumonia, tonsillitis, sinusitis and pharyngitis. · skin and soft tissue infections such as folliculitis, cellulitis and erysipelas. · disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localized infections due to mycobacterium chelonae, mycobacterium fortuitum, or mycobacterium kansasii. · prevention of disseminated mycobacterium avium complex infection in hiv-infected patients with cd4 lymphocyte counts less than or equal to 100/mm3. · clarithromycin in the presence of acid suppression is indicated for the treatment of duodenal ulcer and in reducing the rate of ulcer recurrence.